TUESDAY, December 14, 2021 (HealthDay News) – Pfizer Inc. announced on Tuesday that final analysis shows that his experimental antiviral pill Paxlovid has dramatically reduced hospitalizations and mortality among people at high risk for severe disease.
Recent results, confirming an earlier analysis released in November, Pfizer’s drug has reduced hospitalization and death by nearly 90 percent when taken within three to five days of symptoms, the company said, and preliminary laboratory studies also suggest the pill will last. against the Omicron variant.
“This news provides further confirmation that our oral antiviral candidate, if approved or approved, could have a significant impact on the lives of many, as the data further supports Paxlovid’s effectiveness in reducing hospitalization and death and shows a significant reduction in viral load. This highlights the potential of treatment candidates to save the lives of patients around the world, ”said Pfizer President and CEO Albert Bourla in company statement.
“Emerging variants of concern, such as Omicron, have heightened the need for affordable treatment options for those infected with the virus, and we are convinced that, if approved or approved, this potential treatment could be a critical tool to combat pandemic, “he added.
Two antiviral pills, one from Pfizer and one from Merck, are now under consideration by the U.S. Food and Drug Administration, and decisions on both are expected by the end of the year.
New treatments may not come fast enough: The Omicron variant which is rapidly taking power in South Africa and European countries, has already been discovered in 31 US states. What’s worse, early research suggests that the variant is likely to avoid many of the main treatments doctors have, known as monoclonal antibodies.
Regeneron Pharmaceuticals warned in late November that his cocktail of monoclonal antibodies could be less powerful against Omicron and highlighted his continued efforts on next-generation drugs that are more likely to work against this variant. AND preprint study released on Thursday revealed that omicron could avoid cocktails with antibodies Regeneron, Eli Lilly and AstraZeneca, which last week received authorization for a monoclonal antibody to prevent COVID-19 in people whose immune systems do not respond to vaccines.
In its announcement Tuesday, Pfizer also had good news about people at low risk for severe COVID: In an early analysis, another, ongoing study that tested whether Paxlovid alleviated COVID-19 symptoms more quickly in people who do not consider high- risk has not identified any benefit to alleviate symptoms. But those taking the pill regimen saw the amount of virus in their bodies drop sharply and the pill reduced their already low risk of hospitalization and death. This study included those who were vaccinated and who had at least one risk factor for severe COVID.